Moderna-Merck Melanoma Vaccine Cuts Recurrence Risk by 42% in Phase 3 Trial

Key points

• Intismeran, a personalized mRNA vaccine, reduced the risk of melanoma recurrence or death by 42% when used with Keytruda in a Phase 3 trial.
• The trial enrolled 1,137 patients with stage IIB–IV melanoma across 157 centers, with results presented at the European Society for Medical Oncology in Madrid.
• Moderna’s stock price dropped by approximately 25% after early data leaks, despite positive trial outcomes, reflecting inflated market expectations.
• The vaccine targets neoantigens from cancer-specific mutations, aiming to prevent recurrence in patients who have undergone surgery.
• Long-term survival data is still being monitored, with participants followed for at least 25 months and expected to continue for several years.

Background

Moderna and Merck have been developing intismeran as a personalized cancer vaccine, with earlier Phase 2 trials showing a 49% reduction in recurrence risk. In August 2026, the companies announced positive Phase 3 results, leading to a surge in Moderna’s stock price. The vaccine is designed to complement existing immunotherapies like Keytruda, which has already transformed melanoma treatment by curing nearly 55% of advanced cases.

How outlets are covering it

Nature and Ars Technica emphasize the clinical significance of the 42% risk reduction, noting that oncologists consider a 10% reduction substantial. The Washington Post highlights the potential for a new wave of cancer treatments using mRNA technology. Yahoo Finance focuses on the market reaction, with Moderna’s stock dropping 25% due to inflated expectations, while analysts like Evan Seigerman argue the decline reflects pre-release hype rather than efficacy issues. Goldman Sachs and Morgan Stanley maintain neutral ratings, with price targets below current market levels.

Why it matters

The success of intismeran could establish mRNA technology as a viable platform for personalized cancer treatments, potentially expanding beyond melanoma to other tumor types. The trial’s results may influence regulatory approvals and future clinical strategies, while also impacting the commercial viability of mRNA-based therapies in oncology.

What to watch

Full trial data will be presented at the European Society for Medical Oncology in Madrid on October 24, 2026. Moderna and Merck are engaging with regulatory authorities to seek approval for intismeran. Long-term survival data will continue to be monitored, and statistical analyses will identify which patients benefit most from the treatment.